Back to blog
14 min read

Bipolar Disorder Documentation: SOAP Notes & Medication Management

Dr. Medeline Yost

Dr. Medeline Yost

Chief Medical Officer, Augustun

Published July 11, 2026

Updated July 11, 2026

On this page

Bipolar disorder documentation is not the same as documenting unipolar depression. Every visit should make episode polarity clear — manic, hypomanic, depressive, mixed features, or euthymic — because polarity drives diagnosis coding, medication choice, and safety planning. A note that only says 'stable on lithium' without polarity, sleep, energy, insight, or risk leaves the next clinician guessing and weakens medical necessity.

Mood stabilizer visits also carry lab and toxicity obligations that depression follow-ups often do not. Lithium levels, renal and thyroid function, valproate levels and LFTs, carbamazepine monitoring, and side-effect review belong in the record with dates and clinical interpretation — not as an afterthought. When risk rises in mania or hypomania, the chart must show what you asked, what you observed, and what you did.

This guide focuses on bipolar SOAP notes and medication-management documentation. It complements our general psychiatric SOAP note template, depression progress note guidance, and psychiatric medication management note overview. For the broader psychiatry documentation landscape, see how to write psychiatry notes.

Why Bipolar Notes Need Polarity, Risk, and Med/Lab Detail

In bipolar care, the clinical question is rarely only 'is the patient depressed?' It is which pole is active, how severe it is, whether mixed features are present, and whether the current regimen is preventing relapse without causing harm. Polarity documentation supports correct ICD-10 coding (for example F31.x with episode and remission status), justifies why an antidepressant was avoided or tapered, and explains why an antipsychotic or mood stabilizer was adjusted.

Risk documentation is especially important when energy, impulsivity, and insight shift. Mania and hypomania can present with grandiosity, poor judgment, substance use, sexual impulsivity, or overspending — while patients may minimize symptoms. Your note should capture both the patient's report and collateral or behavioral signals. Medication and lab detail closes the loop: adherence, side effects, last levels, pending labs, and the clinical decision tied to those results.

  • State current episode polarity and severity (or euthymia / remission status) every visit
  • Document sleep, energy, speech, insight, and functional impact as polarity markers
  • Screen explicitly for suicidal and homicidal ideation, plus mania-specific safety concerns
  • Record adherence, side effects, and recent or ordered labs with interpretation
  • Link every medication change to polarity, response, tolerability, and risk

Bipolar I vs Bipolar II: What Changes in the Note

Bipolar I and Bipolar II share mood cycling, but the documentation emphasis differs. Bipolar I requires a history of mania (or a manic episode that was treated), while Bipolar II requires hypomania plus major depression — never full mania. Your chart should make that distinction explicit so coding, differential reasoning, and treatment intensity match the diagnosis.

Documentation focusBipolar I DisorderBipolar II Disorder
Defining historyAt least one manic episode (may include hospitalization, psychosis, marked impairment)At least one hypomanic episode plus major depressive episode; no history of mania
Current episode languageManic, hypomanic, depressed, mixed features, or in remission — with severityHypomanic, depressed, mixed features, or in remission — document why criteria for mania are not met
Functional impactOften marked occupational/social impairment or need for hospitalization during maniaHypomania may feel 'productive'; depression often drives disability — document both poles
Safety emphasisImpulsivity, psychosis, aggression, reckless behavior, SI during depressive polesSI risk during depression; hypomania may still impair judgment — do not minimize
Common coding pitfallOmitting most-recent-episode and remission status from F31 codesMislabeling hypomania as mania, or treating as MDD without bipolar history
Med-management note tipJustify antipsychotics, lithium, and hospitalization thresholds clearlyJustify mood stabilizer choice and caution with antidepressant monotherapy

Document the lifetime history once, then update status

The intake should establish Bipolar I vs II with supporting episode history. Follow-up notes can briefly restate the diagnosis and focus on current polarity, change since last visit, and treatment response — without rewriting the entire longitudinal story each time.

What to Capture Every Bipolar Visit

A repeatable visit checklist keeps bipolar documentation consistent across providers and visit types. Use the patient's words for mood and sleep when possible, then add your objective findings.

ElementWhat to documentWhy it matters
PolarityManic, hypomanic, depressive, mixed features, euthymic / remissionDrives diagnosis coding, med choice, and risk framing
SleepHours slept, need for sleep, insomnia or hypersomnia, day/night reversalCore relapse marker for mania/hypomania and depression
Energy / activationIncreased energy, restlessness, fatigue, psychomotor changeSeparates poles and supports DSM criteria
InsightAwareness of illness, recognition of mood shift, acceptance of treatmentPredicts adherence risk and safety planning needs
SI / HIIdeation, plan, intent, means; protective factors; change since last visitStandard of care every psychiatric visit
AdherenceMissed doses, partial adherence, intentional stops, pharmacy gapsExplains breakthrough symptoms and guides Plan
Side effectsTremor, sedation, weight, cognitive dulling, rash, GI, sexual, metabolicJustifies dose changes and monitoring

Also capture speech rate/pressure, racing thoughts or flight of ideas, impulsivity (spending, sex, driving, substance use), irritability vs elevated mood, and occupational or relationship impact. For depressive poles, include anhedonia, guilt, concentration, appetite/weight, and psychomotor change — the same domains you would track in a depression progress note, with bipolar context preserved.

Scales: YMRS, PHQ-9, and Mood Charting

Measurement-based care makes polarity and response visible over time. Choose scales that match the active pole, and document both the score and a one-line interpretation.

Young Mania Rating Scale (YMRS)

Use YMRS when mania or hypomania is suspected or being tracked. Record the total score, note which items drove elevation (elevated mood, increased motor activity, sleep, speech, content, irritability), and compare to the prior visit. A falling YMRS with restored sleep and linear thought process supports a treatment-response narrative.

PHQ-9 for depressive poles

PHQ-9 remains useful in bipolar depression. Document the score, item 9 (suicidal ideation) explicitly, and whether depressive symptoms coexist with manic/hypomanic features (mixed features). Do not let a high PHQ-9 alone convert the visit into an unipolar depression note — restate bipolar diagnosis and polarity.

Mood charting

Patient mood charts (daily mood, sleep hours, meds taken, stressors) provide longitudinal data between visits. In the Subjective section, summarize trend rather than pasting raw days: for example, 'Patient mood chart shows 5 nights of 4-hour sleep and rising activity preceding this visit.' Note whether the chart was reviewed and how it influenced the Plan.

Pair numbers with clinical meaning

Write 'YMRS 18 (moderate hypomanic range; driven by reduced sleep need, pressured speech, and irritability), down from 24 two weeks ago' rather than listing a score alone. Reviewers and covering clinicians need the trajectory.

Lithium and Mood Stabilizer Lab Monitoring Documentation

Lab monitoring is a documentation obligation, not optional context. Every med-management note for lithium or other mood stabilizers should show what was last checked, when, the result, and what you are doing about it — continue, adjust, recheck, or hold.

MedicationKey labs / monitoringWhat to write in the note
LithiumSerum lithium level, BMP/renal function, TSH, pregnancy test when indicated; levels after dose changes or intercurrent illnessLast level with date and trough timing if known; creatinine/eGFR and TSH; toxicity symptoms reviewed (tremor, GI, ataxia, confusion); hydration/NSAID counseling
Valproate / divalproexDrug level, LFTs, CBC (platelets), pregnancy test when indicatedLevel and date; LFT/CBC status; weight, sedation, tremor; teratogenicity counseling if relevant
Carbamazepine / oxcarbazepineDrug level (CBZ), CBC, LFTs, sodium (especially oxcarbazepine)Level/date; hyponatremia risk; drug interactions reviewed
LamotrigineClinical monitoring for rash; dose titration history; interacting meds (e.g., valproate)Rash reviewed; titration stage; interactions that affect dosing
Atypical antipsychoticsMetabolic labs (glucose/A1c, lipids), weight/BMI, AIMS when indicatedMetabolic panel dates/results; EPS/akathisia; indication for continued antipsychotic

When a level is pending, document that explicitly and set a follow-up action. When a level is subtherapeutic or toxic, state the clinical response: dose change, hold, hydration advice, urgent evaluation, or closer follow-up. Ambiguous phrases like 'labs okay' without dates or values are a common audit weakness.

SOAP Template for Bipolar Medication Management

Use this skeleton for outpatient bipolar med-management visits. Adapt length to acuity; do not skip polarity, risk, or monitoring.

Bipolar Medication Management — SOAP Template

S (Subjective)
Interval history and current polarity in the patient's words. Sleep hours and sleep need. Energy, mood, irritability, racing thoughts, impulsivity, depression symptoms. Functional impact (work, relationships, spending). Adherence and missed doses. Side effects. Substance use. Mood chart summary if reviewed. Direct quotes for impact. SI/HI screen in patient's words.
O (Objective)
MSE with polarity-relevant detail: appearance, behavior, speech rate/pressure, mood and affect, thought process (linear vs flight of ideas), thought content (grandiosity, delusions), perception, cognition, insight, judgment. YMRS and/or PHQ-9 with interpretation. Vitals/weight if relevant. Recent lithium or mood-stabilizer labs with dates. AIMS if on antipsychotic.
A (Assessment)
Bipolar I or II with current episode polarity, severity, and remission status; ICD-10 code. DSM criteria supporting current polarity. Response vs partial response vs relapse. Differential (substance-induced, ADHD, borderline personality features, medical contributors) as relevant. Explicit suicide/homicide risk formulation with risk and protective factors. Lab/toxicity status.
P (Plan)
Medication continue/adjust/stop with rationale tied to polarity and labs. Labs ordered and timing. Side-effect and toxicity counseling. Sleep-wake regularity and early-warning signs reviewed. Therapy/referrals. Safety plan and crisis resources. Follow-up interval and what will be reassessed (YMRS/PHQ-9, levels, risk).

Four Bipolar SOAP Note Examples

Names and details are illustrative. Each example shows how polarity, risk, and med/lab detail should appear in a complete note.

Example 1 — Depressive Episode Follow-Up

Jordan, 34, Bipolar II, returns for worsening depression while on lamotrigine. Focus: depressive polarity, PHQ-9 item 9, and avoiding antidepressant monotherapy without rationale.

Bipolar SOAP — Depressive Episode Follow-Up

S (Subjective)
34-year-old with Bipolar II Disorder returns for 4-week follow-up. Reports 3 weeks of low mood and anhedonia: 'I can't get interested in anything.' Sleeping 10–11 hours, low energy, poor concentration, guilt about falling behind at work. Denies racing thoughts, decreased need for sleep, or impulsivity. Taking lamotrigine 200 mg daily; no missed doses. No new rash. States, 'Some days I wish I wouldn't wake up, but I wouldn't do anything — my partner needs me.' No substance use.
O (Objective)
Casually dressed, psychomotor slowing. Speech soft, normal rate, no pressure. Mood 'depressed'; affect constricted and congruent. Thought process linear; no flight of ideas or grandiosity. No psychosis. Oriented x3; concentration mildly impaired. Insight good; judgment intact. PHQ-9 = 18 (item 9 = 1, passive). YMRS = 2. No rash on exam.
A (Assessment)
Bipolar II Disorder, current episode depressed, moderate (F31.81). Meets depressive criteria with anhedonia, hypersomnia, low energy, impaired concentration, and guilt; no current hypomanic symptoms. Passive SI without plan or intent. Protective factors: partner support, adherence, treatment engagement. Low-to-moderate acute suicide risk. Partial coverage on lamotrigine monotherapy; depressive pole active.
P (Plan)
Continue lamotrigine 200 mg daily. Add quetiapine 50 mg qHS, titrate as tolerated for bipolar depression and sleep consolidation — discussed metabolic monitoring and sedation. Deferred antidepressant given bipolar diagnosis and lack of mood-stabilizer failure. Reviewed safety plan; crisis resources provided; patient agrees to contact clinician or crisis line if passive ideation intensifies. Repeat PHQ-9 in 2 weeks. Follow-up in 2 weeks; sooner if SI worsens or hypomanic symptoms emerge.

Example 2 — Hypomania Check

Priya, 29, Bipolar I, calls in early for reduced sleep and increased goal-directed activity. Focus: hypomania criteria, YMRS, insight, and impulsivity/safety.

Bipolar SOAP — Hypomania Check

S (Subjective)
29-year-old with Bipolar I Disorder presents early for 'feeling wired.' Reports 5 nights of 4–5 hours sleep without feeling tired, increased energy, starting three new projects at once, and talking more than usual. Partner notes irritability. Mild overspending (~$400 on nonessential items) but no reckless driving or sexual impulsivity. Continues lithium 900 mg qHS; states she missed 2 doses last week while traveling. Denies SI/HI. Insight partial: 'I feel productive, but I know this is how my highs start.'
O (Objective)
Well-groomed, restless in seat. Speech mildly pressured, interruptible. Mood 'great but edgy'; affect bright, slightly labile. Thought process circumstantial with mild flight of ideas; no delusions. No hallucinations. Oriented x3. Insight fair; judgment mildly impaired regarding sleep and spending. YMRS = 16. PHQ-9 = 3. Last lithium level 0.7 mEq/L (3 weeks ago); BMP pending today.
A (Assessment)
Bipolar I Disorder, current episode hypomanic (F31.0). Symptoms for ≥4 days with decreased need for sleep, increased energy, pressured speech, goal-directed hyperactivity, irritability, and mild spending — change from euthymia, not severe enough for mania (no hospitalization threshold, no psychosis, functioning impaired but not marked). Missed lithium doses likely contributory. Suicide/homicide risk: denies ideation — currently low, but hypomania elevates impulsivity risk. Close outpatient monitoring indicated.
P (Plan)
Reinforced lithium adherence; continue 900 mg qHS pending today's level. Add olanzapine 2.5 mg qHS short-term for sleep restoration and hypomanic activation; discuss metabolic effects and plan time-limited use. Sleep hygiene and stimulus reduction; partner included with patient consent for early-warning monitoring. Safety: no SI/HI; advised against major financial decisions; remove excess credit access discussed. Recheck lithium level and BMP today; call with results. Follow-up in 5–7 days with repeat YMRS; ED precautions if sleep collapses further, psychosis, or escalating impulsivity.

Example 3 — Lithium Monitoring Visit

Marcus, 47, euthymic on lithium maintenance. Focus: level interpretation, renal/thyroid monitoring, toxicity screen, and relapse-prevention counseling.

Bipolar SOAP — Lithium Monitoring Visit

S (Subjective)
47-year-old with Bipolar I Disorder, maintenance visit. Mood stable for 4 months: 'I finally feel like myself.' Sleeping 7–8 hours, energy steady, no racing thoughts or depression. Taking lithium 600 mg BID and quetiapine 25 mg qHS as prescribed; no missed doses. Mild fine tremor; denies nausea, diarrhea, ataxia, or confusion. Drinks water regularly; avoids NSAIDs per prior counseling. Denies SI/HI.
O (Objective)
Well-groomed, calm. Speech normal rate/volume. Mood 'stable'; affect full and congruent. Thought process linear; no grandiosity. No psychosis. Insight and judgment good. Fine postural tremor, no ataxia. YMRS = 1; PHQ-9 = 2. Lithium level 0.8 mEq/L (trough, drawn this morning). Creatinine 1.0 mg/dL (stable), eGFR >60, TSH 2.1 (3 months ago). Weight stable.
A (Assessment)
Bipolar I Disorder, in full remission, most recent episode manic (F31.74). Euthymic on lithium plus low-dose quetiapine. Lithium level therapeutic; renal function stable; no clinical toxicity. Mild tremor without functional limitation. Suicide/homicide risk: denies ideation — low risk. Maintenance phase; goal is relapse prevention and continued lab safety.
P (Plan)
Continue lithium 600 mg BID and quetiapine 25 mg qHS. Reviewed toxicity symptoms and hydration/NSAID precautions. Tremor acceptable to patient; no dose change. Next lithium level and BMP in 3 months; TSH due in 3 months (order placed). Early-warning signs reviewed (sleep loss, spending, irritability). Continue monthly therapy. Follow-up in 12 weeks; return sooner for fever/GI illness (hold and recheck level guidance provided) or emerging mood symptoms.

Example 4 — Mixed Features / Partial Response

Elena, 41, Bipolar I with depressive symptoms plus concurrent hypomanic features. Focus: mixed features language, partial response, and a plan that addresses both poles.

Bipolar SOAP — Mixed Features / Partial Response

S (Subjective)
41-year-old with Bipolar I Disorder returns 3 weeks after starting lurasidone 40 mg with food for bipolar depression. Mood remains low and tearful, but she also reports inner agitation, racing thoughts at night, and only 5 hours of sleep. Appetite down; concentration poor. No frank euphoria. States, 'I feel miserable and restless at the same time.' Adherent to lurasidone and lithium 900 mg qHS. Mild nausea after lurasidone. Denies SI plan/intent; endorses fleeting passive thoughts. No substance use.
O (Objective)
Tense posture, fidgeting. Speech mildly rapid. Mood 'awful and wired'; affect dysphoric, labile. Thought process linear with racing thought content; no delusions. No hallucinations. Insight fair; judgment intact regarding safety. PHQ-9 = 16 (item 9 = 1). YMRS = 12 (sleep, irritability, speech, content). Lithium level 0.75 mEq/L (1 week ago). BMP within normal limits.
A (Assessment)
Bipolar I Disorder, current episode depressed with mixed features, partial response (F31.13). Depressive symptoms persist with concurrent hypomanic-spectrum activation (reduced sleep, racing thoughts, agitation, elevated YMRS) without meeting full mania. Passive SI without plan/intent; protective factors include adherence and treatment engagement — low-to-moderate risk requiring close follow-up. Lithium therapeutic; lurasidone partially effective with residual mixed features and GI side effect.
P (Plan)
Increase lurasidone to 60 mg with food for incomplete depressive response; counsel on akathisia and nausea. Continue lithium 900 mg qHS. Consider short-term adjunct for sleep if insomnia persists at next visit. Safety plan reviewed; passive SI reassessed — patient agrees to crisis contact if ideation intensifies. Avoid antidepressant add-on while mixed features present. Repeat PHQ-9 and YMRS in 1 week. Follow-up in 7–10 days; sooner for worsening activation, insomnia <4 hours, or escalating SI.

Safety Documentation in Mania and Hypomania

Standard SI/HI screening is necessary but not sufficient when activation is rising. Mania and hypomania create risk through impulsivity, impaired insight, psychosis, aggression, and reckless behavior — even when the patient denies wanting to die.

  • Document sleep trajectory and whether the patient recognizes it as a warning sign
  • Ask specifically about spending, driving, sexual impulsivity, substance use, and aggression
  • Record insight and judgment explicitly — 'denies problems' is not the same as intact insight
  • Note psychosis, command content, or grandiose plans that could harm self/others
  • State the level of care decision (outpatient with close follow-up vs ED/inpatient) with rationale
  • Include collateral when available and whether the patient consented to involve supports
  • Update the safety plan for mania-specific steps (med adherence, sleep restoration, financial limits, crisis contacts)

If the patient is hypomanic and minimizing, write the discrepancy: patient describes feeling 'productive,' while MSE shows pressured speech and the partner reports two nights without sleep. That contrast is clinically meaningful and defensible.

Common Bipolar Documentation Mistakes

Omitting episode polarity

Writing 'Bipolar disorder, stable' without manic, hypomanic, depressive, mixed, or euthymic status fails coding specificity and clinical communication. Name the pole every visit.

Treating bipolar depression like unipolar MDD

A PHQ-9-focused note that never mentions bipolar history, antidepressant risks, or mood-stabilizer status looks like the wrong illness. Keep bipolar framing visible in Assessment and Plan.

Labs without dates or interpretation

'Lithium OK' is not documentation. Record the value, date, trough timing when known, related renal/thyroid results, and the decision that follows.

Skipping mania-specific safety questions

Denying SI does not rule out dangerous impulsivity. Chart what you asked about judgment, spending, aggression, and psychosis.

Medication changes without rationale

Every start, stop, or titration should answer a problem in the Assessment — breakthrough polarity, partial response, side effects, or levels — so medical necessity is obvious.

Copy-forward euthymia during a relapse

Stale MSE language ('speech normal, mood euthymic') during clear hypomania is a quality and liability problem. Update Objective findings to match today's exam.

Let Augustun Draft Your Bipolar Med-Management Notes

Bipolar visits pack polarity, risk, adherence, side effects, and lab interpretation into a short appointment. That is exactly where an ambient AI scribe helps. Augustun for psychiatry listens during the encounter and drafts a structured SOAP note — including mental status detail, scale scores you dictate, and a plan tied to your clinical reasoning — so you can stay present with the patient and still leave with a complete chart.

Augustun supports SOAP and other behavioral health formats, suggests ICD-10 guidance, and connects to 400+ EHRs through a browser extension so finished notes land where you already work. It is built for clinical use with HIPAA compliance, and recordings are never stored. You always review, edit, and sign.

Built for behavioral health privacy

Psychiatric and bipolar documentation is highly sensitive. Augustun is designed for behavioral health workflows with HIPAA-compliant handling, no retained recordings, and clinician review before anything is finalized. Comparing tools? See the best AI scribe for psychiatry roundup, or start from our psychiatric SOAP note and psychiatric medication management note guides.

AI-Powered · HIPAA-Ready

Document bipolar visits without losing polarity or lab detail

Augustun drafts psychiatry-ready SOAP notes from the visit conversation so you can capture episode status, risk, and medication monitoring without staying late to chart. Explore [Augustun for psychiatry](/specialties/psychiatry).

No credit card required.

Conclusion

Strong bipolar documentation makes polarity unmistakable, treats risk as more than a yes/no SI checkbox, and ties medication decisions to adherence, side effects, and timed lab results. Use Bipolar I vs II language accurately, score what you are treating with YMRS and PHQ-9, and keep lithium and mood-stabilizer monitoring visible in every maintenance visit.

Start from the template above, adapt one of the four examples to your patient, and keep the same checklist every visit: polarity, sleep, energy, insight, SI/HI, adherence, side effects, and labs. Whether you write the note yourself or use an AI scribe to draft it, clear bipolar notes protect patients, support medical necessity, and give the next clinician a record they can act on.

Frequently asked questions

What should every bipolar progress note include?

Document current episode polarity (manic, hypomanic, depressive, mixed features, or euthymic/remission), sleep and energy, insight, explicit SI/HI screening, medication adherence and side effects, relevant scale scores (YMRS and/or PHQ-9), and any mood-stabilizer labs with dates and interpretation. Tie the Plan to those findings.

How do you document Bipolar I vs Bipolar II?

State the diagnosis clearly and support it with lifetime history: Bipolar I requires a manic episode (often with marked impairment, hospitalization, or psychosis); Bipolar II requires hypomania plus major depression without a history of mania. Follow-up notes should still name the diagnosis and current polarity so coding and treatment rationale stay accurate.

How should lithium levels be documented?

Record the serum lithium value, date, and trough timing when known; include related renal function and TSH results; note toxicity symptoms reviewed; and state the clinical decision (continue, adjust, hold, recheck). Avoid vague phrases like 'labs okay' without values or dates.

What scales are useful for bipolar medication management?

YMRS tracks mania and hypomania; PHQ-9 tracks depressive poles and item 9 suicide risk. Mood charts between visits help summarize sleep and mood trends. Always interpret scores in the note — include trajectory since the last visit, not only a number.

Can an AI scribe help with bipolar SOAP notes?

Yes. An ambient AI scribe like Augustun can draft a structured bipolar med-management SOAP note from the encounter, including MSE detail and plan elements you discuss, while you remain responsible for reviewing polarity, risk, and lab documentation before signing. Augustun is HIPAA compliant, does not store recordings, and integrates with 400+ EHRs via browser extension.

AI-Powered · HIPAA-Ready

Spend more time with patients, not paperwork.

Augustun transforms ambient speech into accurate notes — finished before your next session.

No credit card required.

Dr. Medeline Yost

Dr. Medeline Yost

Chief Medical Officer, Augustun

Dr. Medeline Yost is an Internal Medicine physician and an emerging leader in clinical innovation. As Chief Medical Officer at Augustun, she helps shape AI-powered tools that streamline clinical documentation and support physicians in delivering higher-quality care. Her professional interests include medical education, workflow redesign, and the responsible use of AI in healthcare — building systems that let clinicians spend more time with patients and less on administrative tasks.